Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Farmers Insurance
Chubb
Queensland Health
Cipla
Boehringer Ingelheim
Teva
Mallinckrodt

Generated: July 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021660

« Back to Dashboard

NDA 021660 describes ABRAXANE, which is a drug marketed by Abraxis Bioscience and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ABRAXANE profile page.

The generic ingredient in ABRAXANE is paclitaxel. There are sixty-nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.
Summary for 021660
Tradename:ABRAXANE
Applicant:Abraxis Bioscience
Ingredient:paclitaxel
Patents:12
Formulation / Manufacturing:see details
Pharmacology for NDA: 021660
Physiological EffectMicrotubule Inhibition
Medical Subject Heading (MeSH) Categories for 021660
Suppliers and Packaging for NDA: 021660
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660 NDA Abraxis BioScience, LLC 68817-134 N 68817-134-50

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;IV (INFUSION)Strength100MG/VIAL
Approval Date:Jan 7, 2005TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 6, 2020
Regulatory Exclusivity Use:TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
Patent:➤ Sign UpPatent Expiration:Feb 21, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF PANCREATIC CANCER
Patent:➤ Sign UpPatent Expiration:Oct 27, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF BREAST CANCER

Expired US Patents for NDA 021660

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
US Army
Medtronic
Chinese Patent Office
Fuji
UBS
Federal Trade Commission
Queensland Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.